THE 2019
CPCC/UCSF PATIENT CONFERENCE
ON PROSTATE CANCER

Presented by The California Prostate Cancer Coalition
and the Helen Diller Family
Comprehensive Cancer Center, UCSF

June 8, 2019 • Cole Hall, UCSF, San Francisco, California
WELCOME TO THE 2019 CPCC /UCSF PATIENT CONFERENCE ON PROSTATE CANCER!

June 8, 2019

STEERING COMMITTEE

The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center warmly welcome you to the 2019 Patient Conference on Prostate Cancer, a National Conference intended for patients, families, caregivers, health care professionals and advocates throughout the country. Thank you to UCSF for graciously offering its Parnassus Campus for this Conference.

In January 2017 at the CPCC Face-to-Face Board Meeting in San Francisco, while prioritizing what activities the CPCC Board should plan, it was suggested that CPCC hold a statewide prostate cancer symposium that would take place in California but be open to others across the country. At subsequent Board Calls the idea took hold and it was tentatively envisioned for the first half of 2019.

In the Fall of 2018, CPCC Board Member Stan Rosenfeld, who is also Chair of UCSF’s Urology Patient Services Committee, mentioned to UCSF’s Dr. Eric Small, who works with that Committee, that CPCC was going to plan a statewide conference on prostate cancer. Dr. Small was ecstatic because he’d been wanting to do something very similar. In late Fall 2018, CPCC Board Members Merel Nissenberg, Tom Kirk and Stan Rosenfeld attended the UCSF Prostate Cancer Retreat and at its conclusion met with Dr. Small to start the planning process. Many months, telephone calls, e-mails and other correspondence later, together we are here today to present The 2019 Patient Conference on Prostate Cancer, a National Conference for Patients, Families, Caregivers, Health Care Providers and Advocates, from across the country, with the theme: “Using current and cutting-edge information to help make informed decisions.” Our Faculty is among the best in the nation. The Agenda is strong. We hope you find this Conference valuable and unique, and we are glad that you’re here!

EDUCATIONAL OBJECTIVE

At the conclusion of this Patient Conference on Prostate Cancer, attendees should be aware of the basics of prostate cancer; fundamentals of testing (genetic, genomic and other tests and imaging); fundamentals of treatment for different stages of prostate cancer, including clinical trials; the importance of a healthy lifestyle (diet, exercise) in addressing prostate cancer; how to manage side effects from diagnosis and treatment; and how to ensure that patients have appropriate access to care for their disease, whether being treated at an academic center or in a community setting. This information should then enable patients - and those that help them make treatment choices - to make informed, individualized decisions with their physicians.
SPECIAL LUNCH LECTURE
BY JOSEPH SCHERGER, MD, MPH
“Working With Your Primary Care Physician”

Joseph E. Scherger, MD, MPH, a long-time Board Member of the California Prostate Cancer Coalition, is a family physician with Primary Care 365 at the Eisenhower Health Center in La Quinta, CA. He is also a core faculty with the Eisenhower Health Family Medicine Residency Program. Dr. Scherger is Clinical Professor of Family Medicine at the Keck School of Medicine at the University of Southern California (USC). Dr. Scherger is a leader in transforming office practice and has special interests in nutrition and using lifestyle change to reverse disease. He is the author of two books, 40 Years in Family Medicine (2014) and Lean and Fit: A Doctor’s Journey to Healthy Nutrition and Greater Wellness (Third Edition, 2019). Dr. Scherger is a Senior Fellow with the Estes Park Institute.

Dr. Scherger graduated from the University of Dayton in 1971, summa cum laude. He graduated from the UCLA School of Medicine in 1975, and was elected to Alpha Omega Alpha. He completed a Family Medicine Residency and a Masters in Public Health at the University of Washington in 1978. From 1978-80, he served in the National Health Service Corps in Dixon, California, as a migrant health physician. From 1981-92, Dr. Scherger divided his time between private practice in Dixon and teaching medical students and residents at UC Davis. From 1988-91, he was a Fellow in the Kellogg National Fellowship Program, focusing on health care reform and quality of life. From 1992-1996, he was Vice President for Family Practice and Primary Care Education at Sharp HealthCare in San Diego. From 1996-2001, he was the Chair of the Department of Family Medicine and the Associate Dean for Primary Care at the University of California Irvine. From 2001-2003, Dr. Scherger served as founding dean of the Florida State University College of Medicine.

Dr. Scherger has received numerous awards, including being recognized as a “Top Doc” in San Diego for six consecutive years, 2004-2009. He was voted Outstanding Clinical Instructor at the University of California, Davis School of Medicine in 1984, 1989 and 1990. In 1989, he was Family Physician of the Year by the American Academy of Family Physicians and the California Academy of Family Physicians. In 1986, he was President of the Society of Teachers of Family Medicine. In 1992, Dr. Scherger was elected to the National Academy of Medicine (Institute of Medicine) of the National Academy of Sciences. In 1994, he received the Thomas W. Johnson Award for Family Practice Education from the American Academy of Family Physicians. In 2000, he was selected by the UC Irvine medical students for the AAMC Humanism in Medicine Award. He received the Lynn and Joan Carmichael Recognition Award from the Society of Teachers of Family Medicine in 2012. In 2016 Dr. Scherger received the Desert Health Integrative Practitioner Wellness Award. He was the 2017 President of the Riverside County Medical Association.

Dr. Scherger served on the Institute of Medicine Committee on the Quality of Health Care in America from 1998-2001. Dr. Scherger served on the Board of Directors of the American Academy of Family Physicians and the American Board of Family Medicine. Dr. Scherger currently serves on the editorial board of Medical Economics and was an Assistant Editor of Family Medicine from 2010-2017. He was the Men’s Health expert and a consultant for Revolution Health, 2006-09, and he has covered California for eDocAmerica since 2003. He was Editor-in-Chief of Hippocrates, published by the Massachusetts Medical Society, from 1999-2001. He was the first Medical Editor of Family Practice Management. He has authored more than 500 medical publications and has given over 1100 invited presentations.
The California Prostate Cancer Coalition (CPCC) was organized in 1997 as a 501(c)(3) not-for-profit organization, made up of prostate cancer patients, family members, health care providers and other individuals interested in prostate cancer throughout the State of California. We are saving men’s lives and enhancing the quality of life for men and their families!

The Board of the California Prostate Cancer Coalition (CPCC) is composed of individuals from Northern, Central, and Southern California, and it meets monthly with up to two Face-to-Face Meetings each year. CPCC is a Proud Participant in the National Alliance of State Prostate Cancer Coalitions (NASPCC). CPCC President, Merel Nissenberg, also serves as President of NASPCC. CPCC Vice President Tom Kirk also serves as an Invited Member of NASPCC’s Executive Committee.

What does CPCC do as part of its Mission?

- We advocate for the early detection of potentially deadly prostate cancer
- We are making prostate cancer a key health care priority in California
- We network all the prostate cancer support groups in the state
- We disseminate information relating to prostate cancer, including a durable, laminated awareness and education tool. www.prostatecalif.org/patient-guide
- We advocate for prostate cancer legislation and funding and helped make IMPACT for underserved men a permanent California state program
- We advocate for the highest quality of life for prostate cancer patients and their families
- We perform outreach to, and involve all communities
- We publish a newsletter
- We maintain a website: www.prostatecalif.org
- We conduct annual workshops for prostate cancer support groups

CPCC BOARD OF DIRECTORS 2018-2019

Frank Balthis; Arthur “Tony” Blain, MD; Barry Chauser, MD; Marc Dall’Era, MD; William Doss; Joe Ferrara; Earl H. Jones, Jr. (Treasurer); Thomas Kirk (Vice President); Arthur Lurvey, MD; Carol Marcusen; Leonard S. Marks, MD; Beverly Nicholson; Merel Grey Nissenberg, Esq. (President); Tiffany Razzo (Secretary); Stan Rosenfeld; Joseph E. Scherger, MD, MPH; Westley Sholes; and Sam Wells

For more information, contact us at 415-459-4668 or send an e-mail to cpcc@prostatecalif.org.

Left to Right: William Doss, Westley Sholes, Tiffany Razzo, Beverly Nicholson, Tom Kirk, Merel Grey Nissenberg, Stan Rosenfeld, Ericka Maldonado-Aviles, guest speaker, and Earl Jones
HELEN DILLER FAMILY
COMPREHENSIVE CANCER CENTER

In 1948, the University of California at San Francisco (UCSF) established the Cancer Research Institute, a precursor to consolidation of its cancer activities in more recent decades. NCI designation as a comprehensive cancer center came in 1999 and the Center was renamed the UCSF Helen Diller Family Comprehensive Cancer Center in 2007.

The UCSF Helen Diller Family Comprehensive Cancer Center was the first center in the Bay Area to receive the prestigious designation of “comprehensive” from the National Cancer Institute. The Helen Diller Family Comprehensive Cancer Center treats all forms of cancer. With new facilities, expanded programs and innovative research, it helps cancer patients live longer and fuller lives. UCSF Helen Diller Family Comprehensive Cancer Center is an NCI-designated Cancer Center, affiliated with the UCSF School of Medicine and the UCSF Medical Center. It is one of 69 cancer research institutions in the United States supported by the National Cancer Institute, and one of three in Northern California. The Helen Diller Family Comprehensive Cancer Center provides exceptional patient care at: UCSF Medical Center at Mount Zion, UCSF Medical Center at Mission Bay, UCSF Medical Center at Parnassus, Zuckerberg San Francisco General Hospital, and the San Francisco Veterans Affairs Medical Center.

The UCSF Helen Diller Family Comprehensive Cancer Center combines basic science, clinical research, epidemiology/cancer control and patient care from throughout the University of California, San Francisco system. UCSF’s long tradition of excellence in cancer research includes the Nobel Prize-winning work of J. Michael Bishop and Harold Varmus, who discovered cancer-causing oncogenes. Their work opened new doors for exploring genetic abnormalities that cause cancer, and formed the basis for some of the most important cancer research happening today.

Basic Scientific Research
From understanding normal cellular processes to discovering the underlying molecular and genetic causes of cancer when these processes go awry, UCSF researchers are committed to moving scientific insights forward and pursuing their relevance for clinical oncology and cancer prevention.

Clinical Research
Clinical scientists explore how a greater understanding of fundamental biological events can be transformed into clinical tools. New forms of cancer treatment, as well as innovations in diagnosis and prognosis, undergo rigorous evaluation for safety and efficacy. This translates into improved patient outcomes and hope for the future.

Patient Care
The Helen Diller Family Comprehensive Cancer Center provides exceptional patient care at five San Francisco medical centers: UCSF Medical Center at Mount Zion, UCSF Medical Center at Mission Bay, UCSF Medical Center at Parnassus, Zuckerberg San Francisco General Hospital and Trauma Center, and the San Francisco Veterans Affairs Medical Center.
# AGENDA

## I. THE BASICS: Session Chair, Eric Small, MD

1. Introduction and welcome 8:00 - 8:15
   Merel Nissenberg, Esq, Stan Rosenfeld, Eric Small, MD

2. Prostate Cancer 101: The basics you need to know 8:15 - 8:35
   Peter Carroll, MD, MPH

3. Prostate Cancer Genetics 101 8:35 - 8:55
   Felix Feng, MD

4. Basics of Prostate Cancer Immunology and Immunotherapeutics 8:55 - 9:15
   David Oh, MD

5. Demystifying Clinical Trials: What are they, and what should you think about when considering a trial? 9:15 - 9:35
   Rahul Aggarwal, MD

6. The ABCs of Androgen Deprivation Therapy 9:35 - 9:55
   Eric Small, MD

### MORNING BREAK 9:55 - 10:15

## II. TREATMENT OF NON-METASTATIC DISEASE BASED ON RISK ASSESSMENT:

### Session Chair, Peter Carroll, MD

7. Disease Location and Risk Assessment: the scientific tools available to help with clinical decision making 10:15 - 10:45
   Peter Carroll, MD, MPH
   Matt Cooperberg, MD, MPH
   Felix Feng, MD
   Tom Hope, MD

8. Low Risk Localized PCa: Genomic Tests, Focal Treatment and Active Surveillance 10:45 - 11:15
   Peter Carroll, MD, MPH
   Leonard Marks, MD

9. Intermediate and High-risk Disease and multimodal therapy 11:15 - 11:45
   Matt Cooperberg, MD, MPH
   Mack Roach, MD
   Eric Small, MD
   James Yu, MD
AGENDA (continued)

<table>
<thead>
<tr>
<th>Session Name</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SPECIAL LECTURE:</strong></td>
<td></td>
</tr>
<tr>
<td>“Working with Your Primary Care Physician”</td>
<td>11:45 -12:30</td>
</tr>
<tr>
<td>Joseph Scherger, MD, MPH</td>
<td></td>
</tr>
<tr>
<td><strong>LUNCH</strong></td>
<td>12:30 -1:30</td>
</tr>
<tr>
<td>Meet the Professors</td>
<td></td>
</tr>
<tr>
<td>Eric Small, MD</td>
<td></td>
</tr>
<tr>
<td>Peter Carroll, MD, MPH</td>
<td></td>
</tr>
<tr>
<td>Felix Feng, MD</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
</tr>
<tr>
<td><strong>III. A SYSTEMATIC APPROACH TO SYSTEMIC THERAPY:</strong></td>
<td></td>
</tr>
<tr>
<td>Session Chair, Rahul Aggarwal, MD</td>
<td></td>
</tr>
<tr>
<td>10. The optimal treatment of bone metastases</td>
<td>1:30 -1:45</td>
</tr>
<tr>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td>11. New and Developing Treatment Approaches for</td>
<td>1:45 -2:15</td>
</tr>
<tr>
<td>patients with non-localized prostate cancer</td>
<td></td>
</tr>
<tr>
<td>Eric Small, MD</td>
<td>Rahul Aggarwal, MD</td>
</tr>
<tr>
<td>12. The role of Diet and Exercise in addressing</td>
<td>2:15 -2:30</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>June Chan, Sc.D</td>
<td></td>
</tr>
<tr>
<td><strong>AFTERNOON BREAK</strong></td>
<td>2:30 -2:50</td>
</tr>
<tr>
<td><strong>IV. FROM THE PATIENT'S PERSPECTIVE:</strong></td>
<td></td>
</tr>
<tr>
<td>Session Chair, Stan Rosenfeld</td>
<td></td>
</tr>
<tr>
<td>13. Managing the side effects of prostate cancer</td>
<td>2:50 -3:20</td>
</tr>
<tr>
<td>and its treatment</td>
<td></td>
</tr>
<tr>
<td>Alan Shindel, MD</td>
<td>Mike Rabow, MD</td>
</tr>
<tr>
<td>Mike Rabow, MD</td>
<td>Nannette Perez, NP</td>
</tr>
<tr>
<td>14. Access to care and optimizing care received</td>
<td>3:20 -3:50</td>
</tr>
<tr>
<td>from Community Physicians</td>
<td></td>
</tr>
<tr>
<td>Merel Nissenberg, Esq</td>
<td>Tom Kirk, Brad Ekstrand, MD</td>
</tr>
<tr>
<td>Tom Kirk, Brad Ekstrand, MD</td>
<td>David Lowther, MD</td>
</tr>
<tr>
<td>15. Practical tips for the consumer including</td>
<td>3:50 - 4:20</td>
</tr>
<tr>
<td>how to approach decision-making</td>
<td></td>
</tr>
<tr>
<td>Tia Weinberg</td>
<td></td>
</tr>
<tr>
<td>Eric Small, MD and Stan Rosenfeld</td>
<td></td>
</tr>
<tr>
<td>will interview three patients:</td>
<td></td>
</tr>
<tr>
<td>Joe Ferrara, Richard Ridington and Walt Trask</td>
<td></td>
</tr>
<tr>
<td><strong>CLOSING AND WRAP-UP</strong></td>
<td>4:20 – 5:00</td>
</tr>
</tbody>
</table>
CPCC/UCSF PROSTATE CANCER CONFERENCE
FACULTY BIOS

RAHUL AGGARWAL, MD
Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology. Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.

PETER CARROLL, MD, MPH
Dr. Peter Carroll is a Professor and Chair of the UCSF Department of Urology. He received his Medical Degree with Honors from Georgetown University School of Medicine, and came to UCSF for his general surgery training and urology residency. He completed a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center and joined the UCSF Department of Urology in 1986.

Dr. Carroll organized the Urologic Oncology Service, one of the most active multidisciplinary programs at UCSF. In 1996 he assumed the Chair of the UCSF Department of Urology, consistently ranked as one of the top urology departments in the country by U.S. News and World Report. He holds the Ken and Donna Derr-Chevron Distinguished Professorship, and he served as surgeon-in-chief of the UCSF Comprehensive Cancer Center from 2003 through April 2007. In September 20006, Dr. Carroll became the Director of Strategic Planning and Clinical Services of the UCSF Helen Diller Family Comprehensive Cancer Center and Associate Dean, School of Medicine. In May 2008 he earned his MPH from UC Berkeley.

Dr. Carroll has authored or co-authored over 500 publications. He is now Past President of the American Board of Urology (2006-2008). He is currently principal or co-investigator on numerous scientific studies. His major professional interests are the study and management of urologic cancers, innovative methods of urinary tract reconstruction, health services research, health policy and the impact of cancer detection and treatment on quality of life.

Dr. Carroll was awarded the 2010 Eugene Fuller Triennial Prostate Award and the SUO Medal from the AUA and SUO, respectively. In 2014, he was also awarded the coveted Barringer Medal from the American Association of Genitourinary Surgeons. This award recognizes a younger member who is achieving “distinguished accomplishments.” In 2017, he accepted a position as AAGUS Treasurer. He is also the Taube Family Distinguished Professor in Urology Department of Urology.

Dr. Carroll is committed to reducing the burden of prostate cancer treatment – physical, psychological, and monetary. He pioneered and remains a vocal advocate for standardizing an active surveillance regimen in patients with low-volume, early-stage prostate cancer. Active surveillance carefully determines which patients can safely postpone radical treatment while still maintaining an acceptably low risk of cancer progression. At the same time, by improving early prognostic capabilities, Dr. Carroll strives to identify which men may benefit from more aggressive early therapies.

JUNE CHAN, Sc.D
Dr. June Chan earned her AB at Harvard College in applied mathematics, followed by a doctorate in science from the Harvard School of Public Health. She was a Fulbright Scholar in Sweden and completed a post-doctoral fellowship at the Department of Epidemiology at the Harvard School of Public Health. Dr. Chan received a CapCURE (now known as the Prostate Cancer Foundation) Young Investigator Award; and was awarded the Steven and Christine Burd-Safeway Distinguished Professorship in 2009. Dr. Chan is a member of the UCSF Prostate Cancer Center.

Dr. June M. Chan has broad interests in cancer prevention and public health, in particular what individuals can do to modify their risk of chronic disease, co-morbidity, and death. She has expertise and interests in epidemiology and medical education; and has conducted research on diabetes, pancreatic, colon, and prostate cancer.

Dr. Chan’s current research is focused on understanding how diet, exercise, hormones, and genetics contribute to prostate cancer incidence, progression, and death. She is particularly interested in identifying modifiable lifestyle risk factors for prostate cancer progression, and using this information to help us better understand prostate cancer biology as well as inform public health guidelines. The goals of her clinical and translational research studies are to identify risk-reduction strategies for men with or at high risk for prostate cancer; evaluate novel molecular markers of prostate cancer aggressiveness that may improve screening, diagnosis, or prognosis of clinically relevant disease; and improve cancer survivorship for the millions of men living with prostate cancer worldwide.

She is PI of the prospective national Diet and Lifestyle Study within the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), and a multi-site clinic-based cohort study examining nutritional and genetic risk factors for aggressive prostate cancer. She also collaborates with colleagues at the Harvard School of Public Health on the Health Professionals Follow-up Study to examine diet and lifestyle risk factors for prostate cancer progression, metastases, and death.

(continued on next page)
MATTHEW COOPERBERG, MD, MPH
Dr. Matthew Cooperberg received his undergraduate training from Dartmouth College, where he earned a degree in English with high honors. He then enrolled in Yale University’s MD, MPH program, concurrently earning an MPH with a concentration in Health Policy from the School of Epidemiology and Public Health, and a MD from the School of Medicine. He completed his General Surgery and Urology training at the University of California, San Francisco, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology under the guidance of Peter Carroll, MD, MPH. In 2009, Dr. Cooperberg was recruited to join the faculty at UCSF and the San Francisco Veterans Affairs Medical Center. Specializing in urologic cancer care, he is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus. He also maintains privileges at San Francisco General Hospital. In 2013, Dr. Cooperberg received the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award, given annually to one urologist for contributions to the field in the first 10 years of practice, and was also named Young Urologist of the Year. He was named professor in 2018. Dr. Cooperberg’s clinical interests include the early detection, diagnosis, and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. He performs robotic, laparoscopic, endoscopic, and percutaneous surgeries, and is interested in incorporating promising new technologies into his practice. He is particularly interested in risk-stratifying prostate, renal, and other tumors, and matching treatments appropriately to those patients most likely to benefit, using novel imaging tests and biomarkers together with clinical information. Dr. Cooperberg is a Fellow of the American College of Surgeons, and a member of the American Urological Association (AUA) and the Society for Urologic Oncology. In 2012. Dr. Cooperberg co-wrote a proposal to establish a national urology registry. From this proposal developed the AUA Quality (AQUA) Registry, a national database tracking practice patterns, quality of care, and both clinical and patient-reported outcomes for patients across the U.S. with prostate cancer and other urologic conditions. Dr. Cooperberg continues in a senior leadership role with the project. Drawing on the CaPSURE registry, UCSF’s institutional databases, and other data resources, Dr. Cooperberg has written over 295 peer-reviewed scientific articles, and has been invited to present his research findings at many national and international conferences. His primary research focus is prostate cancer, with particular areas of interest including: 1) health services research, documenting ongoing trends and regional variation in the use of diagnostic, imaging, and therapeutic interventions for men with all stages of prostate cancer; 2) risk assessment and biomarker research, developing and validating prognostic tools incorporating both standard clinical information and emerging biomarkers; 3) comparative effectiveness research, examining evidence regarding the relative benefits of surgery, radiation, and other treatments in terms of cancer control, quality of life, and cost; and 4) decision support and survivorship, helping men make better-informed decisions about both treatments and management of short- and long-term treatment sequelae. He is also very interested in disparities in prostate cancer access and outcomes, and in prostate cancer as an international disease. He helped forge a number of inter-continental collaborations which are yielding fascinating insights into prostate cancer’s variation in presentation and outcome around the world. He has received numerous awards for his research papers and is co-investigator on multiple grants. He won a prestigious Young Investigator Award from the Prostate Cancer Foundation, and is a current investigator on a number of ongoing Federal grants including his first R01 as principle investigator, awarded in 2016 to study microRNAs as candidate prostate cancer biomarkers.

BRADLEY EKSTRAND, MD, PhD
Dr. Bradley Ekstrand sees patients at California Cancer Care, combining a scientist’s perspective on the latest in cancer biology with a healer’s ability to care for the whole patient and not just treat the disease. While Dr. Ekstrand sees a wide variety of patients with cancer, he has particular interests in treating patients with genitourinary malignancies and lymphomas.

Dr. Ekstrand earned his MD as well as a Ph.D. (studying cancer biology) from Yale University School of Medicine. He received his B.S. in Chemistry from Stanford University, where he earned Phi Beta Kappa honors. Dr. Ekstrand attended Mount Sinai Medical Center in New York for his Internship and Residency in Internal Medicine. For his Fellowship in Medical Oncology he trained at Stanford University School of Medicine. He has co-authored numerous scientific publications within the field of molecular biology and medical oncology. He is board certified in both Internal Medicine and Medical Oncology.

Dr. Ekstrand has ongoing experience in Phase I, II, III, and IV Clinical Pharmaceutical Trials as a Principal and/or Sub Investigator. He also currently serves on the Board of Directors for the Association of Northern California Oncologists.

FELIX FENG, MD
Dr. Felix Feng, MD, received his undergraduate training from Stanford University, where he earned a degree in Biological Sciences and received a President’s Award for Academic Excellence. He then received his MD from Washington University in St. Louis, where he received numerous awards for his research and academic achievements. He then completed both a postdoctoral research fellowship and his residency in radiation oncology at the University of Michigan, and subsequently joined the faculty there. In addition to being the Director of the Division of Translational Genomics, Dr. Feng also co-led the multidisciplinary clinic for prostate cancer patients and served as Director of the Genitourinary Cancer Program within the Department of Radiation Oncology at the University of Michigan. In 2016, Dr. Feng was recruited to join the faculty at UCSF, where he currently is an Associate Professor of Radiation Oncology, Urology, and Medicine, and serves as Vice Chair for Faculty Development and Director of Translational Research for the Department of Radiation Oncology.

Dr. Feng’s clinical interests include the diagnosis and management of genitourinary malignancies. He specializes in urologic cancer care, with particular areas of interest including: the early detection, diagnosis, and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. He performs robotic, laparoscopic, endoscopic, and percutaneous surgeries, and is interested in incorporating promising new technologies into his practice. He is particularly interested in risk-stratifying prostate, renal, and other tumors, and matching treatments appropriately to those patients most likely to benefit, using novel imaging tests and biomarkers together with clinical information. Dr. Feng is a Fellow of the American College of Surgeons, and a member of the American Urological Association (AUA) and the Society for Urologic Oncology. In 2012, Dr. Cooperberg co-wrote a proposal to establish a national urology registry. From this proposal developed the AUA Quality (AQUA) Registry, a national database tracking practice patterns, quality of care, and both clinical and patient-reported outcomes for patients across the U.S. with prostate cancer and other urologic conditions. Dr. Cooperberg continues in a senior leadership role with the project. Drawing on the CaPSURE registry, UCSF’s institutional databases, and other data resources, Dr. Cooperberg has written over 295 peer-reviewed scientific articles, and has been invited to present his research findings at many national and international conferences. His primary research focus is prostate cancer, with particular areas of interest including: 1) health services research, documenting ongoing trends and regional variation in the use of diagnostic, imaging, and therapeutic interventions for men with all stages of prostate cancer; 2) risk assessment and biomarker research, developing and validating prognostic tools incorporating both standard clinical information and emerging biomarkers; 3) comparative effectiveness research, examining evidence regarding the relative benefits of surgery, radiation, and other treatments in terms of cancer control, quality of life, and cost; and 4) decision support and survivorship, helping men make better-informed decisions about both treatments and management of short- and long-term treatment sequelae. He is also very interested in disparities in prostate cancer access and outcomes, and in prostate cancer as an international disease. He helped forge a number of inter-continental collaborations which are yielding fascinating insights into prostate cancer’s variation in presentation and outcome around the world. He has received numerous awards for his research papers and is co-investigator on multiple grants. He won a prestigious Young Investigator Award from the Prostate Cancer Foundation, and is a current investigator on a number of ongoing Federal grants including his first R01 as principle investigator, awarded in 2016 to study microRNAs as candidate prostate cancer biomarkers.
FACULTY BIOS (continued)

FELIX FENG, MD, (continued)
in the treatment of high-risk aggressive prostate cancers as well as oligometastatic disease. For upfront or post-surgical treatment for patients, his therapeutic approaches include intensity-modulated radiation therapy as well as stereotactic ablative radiotherapy, among many others. Dr. Feng is nationally known for his approaches of using molecular biomarkers to help guide or personalize radiation therapy for patients. He serves as the leader of the Genitourinary Cancer Translational Research Program for the NRG Clinical Trials Group, and is a member of the National Cancer Institute Steering Committee for Genitourinary Cancers. He has helped conduct numerous clinical trials, and is the co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer.

Dr. Feng is a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. His laboratory focuses on identifying and validating biomarkers associated with treatment resistance in prostate cancer patients, and overcoming radiation or hormone therapy resistance with targeted therapy. He has published over 130 peer-reviewed scientific articles, and his major contributions to the medical field include: 1) the development of novel molecular subtyping approaches to distinguish biological subgroups of prostate cancer that differ in treatment response, 2) identification of new drivers of aggressive prostate cancer; 3) the development of novel therapeutic approaches to treat prostate cancer. He has published manuscripts in leading journals such as the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, European Urology, Nature, and Nature Genetics. He has received numerous awards for his research and is the principal investigator on multiple grants, from various federal and foundation sources.

JOE FERRARA
Joe Ferrara is both the owner of Santa Cruz, CA's award winning comic bookstore, Atlantis Fantasyworld, and an accomplished professional musician. He is also a 14-year prostate cancer survivor. He is a member of the steering committee of the Santa Cruz County Prostate Support Group (SCCPSG) and serves on the Board of the California Prostate Cancer Coalition (CPCC).

On Sunday, September 14, 2008, Ferrara launched a unique prostate cancer awareness campaign. He played his guitar and sang 182 songs from memory “continuously” from 10:00 a.m. to 10:00 p.m. at the Shadowbrook Restaurant in Capitola, CA. The 12-hour marathon opened the eyes of the public to the need for screenings and early detection.

In 2016 Joe worked with Marvel Comics to produce a series of comic books with variant covers, featuring the heroes in blue uniforms and a public service announcement about prostate cancer.

In 2017, working with the SCCPSG, the California Prostate Cancer Coalition (CPCC), the National Alliance for State Prostate Cancer Coalitions (NASPCC), and Us TOO, Ferrara was able to place a full page public service announcement about prostate cancer awareness in 25 different comic books published by IDW. The total print run was over 250,000 comics!

Today Joe Ferrara continues to perform Friday nights at the Shadowbrook Restaurant in Capitola and Sunday nights at the Cats Restaurant in Los Gatos. He and his wife, Dottie, serve on the steering committee of the SCCPSG.

TOM HOPE, MD
Dr. Thomas Hope is a radiologist and nuclear medicine physician (an expert in medical applications of radioactive substances). He specializes in neuroendocrine tumors, with a focus on peptide receptor radionuclide therapy, which targets these cancer cells with a high dose of radiation. He has a special interest in molecular imaging and in treating cancer using the targeted, individualized techniques of precision medicine.

In addition to working with patients, Dr. Hope conducts research on novel radiopharmaceuticals, or new radioactive imaging substances that can help physicians locate tumors. He also works on combining different imaging modalities – such as positron emission tomography and MRI to stage cancer in patients.

Dr. Hope received his medical degree from Stanford University School of Medicine. He completed a residency in diagnostic radiology at UCSF. He then completed a fellowship in nuclear medicine and body MRI at Stanford.

Dr. Hope is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, Society of Abdominal Radiology and International Society for Magnetic Resonance in Medicine.

THOMAS KIRK
Tom Kirk has been heavily involved in Patient Advocacy Non-Profit Organizations. He currently serves as the volunteer Vice-President of the California Prostate Cancer Coalition (CPCC), which is “a proud participant” in the National Alliance of State Prostate Cancer Coalitions (NASPCC). CPCC is the co-presenter of this conference: The 2019 CPCC/UCSF Patient Conference on Prostate Cancer. Tom is also an Invited Member of the NASPCC Executive Committee.

Tom Kirk developed the Strategic Plan for NASPCC in 2017 and as Chair of NASPCC’s Steering Committee, he monitors the Plan’s implementation with the NASPCC Committees that were created to move it forward. Tom also serves on the NASPCC Advocacy and Public Policy Committee which, following NASPCC’s 2018 Bone Health Access Initiative (BHI), and the October Bone Health Access Roundtable, prioritized “Step Therapy” as an issue.

In prostate cancer, Tom served as the President and CEO of Us TOO International in suburban Chicago for over 10 years, before moving to California in 2016. He currently works as a Co-Founder of Informed Health Consulting (IHC). Additionally, Tom worked for over 12 years at the National Alzheimer’s Association headquartered in Chicago. He worked on the Senior Management Team where he was the Vice President of Patient, Family and Education Services. He has also assisted other Residential Care Providers (Mather Life Ways and Belmont Village) develop their Dementia Care Services, and he worked as the Vice President of Operations for Life Care Centers of America’s Garden Terrace Associates managing their specialized Dementia-Specific Long-Term Care Centers and Dementia Care Units. Tom holds an MSSW Degree in Planning and Administration from the University of Wisconsin-Madison.

(continued on next page)
**FACULTY BIOS (continued)**

**DAVID LOWTHER, MD**  
David Lowther, MD earned his medical degree from Georgetown University. He went on to complete an internship at University of Miami, Jackson Memorial Hospital and residencies at New England Medical Center, Tufts University and the University of California San Francisco. In practice for over a decade, Dr. Lowther has been extensively involved in research, including authoring numerous articles in peer-reviewed journals on the latest advances in prostate and breast cancer treatment. Dr. Lowther has received numerous awards in his field, including the Oliver Smith Award and the William C. Maxted Award. He was named a Top Doctor in Silicon Valley in 2004 and 2005.

**LEONARD MARKS, MD**  
Dr. Leonard Marks is Professor and inaugural holder of the deKernion Chair in Urology at the David Geffen School of Medicine at UCLA. He graduated from the University of Texas Medical Branch, where he received the MD with AOA honors and M.A. (Physiology) degrees in 1969. He served an internship and surgical residency at UCLA/ Harbor General Hospital. For two years following, he served on active duty as Lt. Cdr. in the U.S. Public Health Service. He was named a Post- Doctoral Research Scholar at UCLA School of Medicine in 1973-4. Dr. Marks completed his urology residency at UCLA and was Lecturer in Urology there in 1978, following which he entered private practice in Los Angeles. He re-joined the UCLA faculty full-time in 2009.

While in practice, Dr. Marks founded a non-profit research organization, Urological Sciences Research Foundation, a 501(c)(3) corporation, to further his academic interests. He became an original AFUD scholar in 1992 for work relating serum PSA levels to prostate histology. He received a Prostate Cancer Foundation (PCF) research award in 2000 for cross-cultural studies of prostate cancer. An early advocate of multimedia in medical education, Dr. Marks served as Website Editor of *Urology* (The Gold Journal) from 1998-2010. For his work in the scientific evaluation of alternative medicines, he was appointed to committees of the American Urological Association, the National Institutes of Health (NCCCAM and NIDDK), and the National Academy of Sciences. He has for the past 8 years been Principle Investigator of three separate R01 Awards from the National Cancer Institute, devoted to targeted prostate biopsy and focal therapy of prostate cancer. He has authored more than 150 scientific publications.

**MEREL GREY NISSENBERG, ESQ.**  
Merel Grey Nissenberg, Esq. is a medical malpractice attorney in Los Angeles handling cases around the country, and she is President of three non-profits in healthcare: the National Alliance of State Prostate Cancer Coalitions (NASPCC); the California Prostate Cancer Coalition (CPCC), both of which she co-founded; and the Clifton F. Mountain Foundation for Education & Research in Lung Cancer. She is a member of two National Cancer Institute SPORES (one in Prostate Cancer at UCLA, one in Lung Cancer at M. D. Anderson Cancer Center), and she is on the UCLA SPORE Executive Committee. She is also the Advocate for the Canary Foundation’s Trial at Stanford (Prostate Active Surveillance) and is part of a PCORI Grant with UCLA dealing with decision aids in prostate cancer. Additionally, through her consulting group Informed Health Consulting she and her partner help accrue patients to Clinical Trials and also create Patient Ambassador Programs and Roundtables. Merel has been actively involved for almost ten years as one of three National Patient Advocates for the Early Detection Research Network (EDRN) of the National Cancer Institute, handling three of the four Collaborative Groups: GU Cancers, GYN Cancers, and Lung Cancer. In her law practice she has represented many cancer patients, and has advocated for them and for their families. Merel is extremely interested in the early detection of cancers when they are still curable and is dedicated to improving the lives of patients, including those as-yet-undiagnosed.

**LEONARD MARKS, MD**  
**DAVID OH, MD**

Dr. David Oh received his undergraduate degree from Harvard College and his Medical Degree from Stanford University School of Medicine. His residency in Internal medicine and his fellowship in hematology/Oncology were at UCSF.

Dr. Oh is a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies. Clinically, he sees patients in the Cancer Immunotherapy Program where he is an attending physician and investigator on early-phase/first-in-human trials testing novel immunotherapies in advanced solid tumors, with a particular focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, and adoptive cell therapies.

In the laboratory, Dr. Oh studies samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment. Dr. Oh is especially interested in immunotherapy for genitourinary malignancies and immune-related adverse events.

**NANNETTE PEREZ, NP**  
Ms. Nannette Perez received her Bachelor of Science in Nursing from the San Francisco State University and her Master of Science in Nursing from UCSF. Nannette Perez provides comprehensive care to patients utilizing advanced clinical assessment and knowledge in the diagnosis, treatment and management of acute and chronic health care problems related to urologic oncology. She has developed and implemented hospital staff and patient education classes on the diagnosis and treatment of prostate cancer for newly diagnosed patients.

She has also participated in community outreach/education programs and events targeting populations at high-risk for prostate cancer. Ms. Perez has lectured at various national nursing conferences on prostate cancer as well as pre and post treatment symptom management. Her prior expertise includes implementing the post award subcontract of a state-funded grant that pays for prostate cancer treatment for uninsured/underinsured men in California (IMPACT). She enjoys teaching and has been a student preceptor over the years for the UCSF School of Medicine.

(continued on next page)
NANNETTE PEREZ, NP, (continued)

Nursing Adult Nurse Practitioner Program and a variety of high school summer health science internship programs.

As the clinical point person of the Active Surveillance Program at the UCSF Helen Diller Family Comprehensive Cancer Center, Nannette Perez along with the surgical faculty sees and provides clinical guidance to over one-thousand participating patients in this prostate cancer management regime. She has also co-authored numerous papers on Active Surveillance for prostate cancer patients in medical journals such as the Journal of Clinical Oncology.

MICHAEL W. RABOW, MD, FAAHPM

Michael W. Rabow, MD, FAAHPM, the Helen Diller Family Chair in Palliative Care, is a Professor of Clinical Medicine and Urology and Associate Chief of Education & Mentoring in the Division of Palliative Medicine, Department of Medicine, at the University of California, San Francisco. Dr. Rabow attended UCSF for medical school and general internal medicine residency training. He completed fellowships at UCSF in general medicine, as well as in medical education research and is board-certified in internal medicine and hospice and palliative care. For 25 years previously, Dr. Rabow was in the Division of General Medicine and continued an active primary care practice along with his work in palliative care.

Dr. Rabow directs a leading outpatient palliative care program - the Symptom Management Service - at the UCSF Helen Diller Family Comprehensive Cancer Center. One of the largest palliative care programs in a cancer center nationally, the Symptom Management Service currently provides outpatient palliative care co-management in more than 30 half-day clinics weekly across three campuses at UCSF. He was the founding director of the UCSF/Mount Zion Hospital and Bakar Hospital Palliative Care Consultation Services.

Dr. Rabow is a national expert in outpatient palliative care research and service delivery. He has conducted both controlled and longitudinal trials of outpatient palliative care consultation, as well as multiple surveys of current outpatient palliative care consultation practices nationally. He is currently part of a PCORI study examining home-based palliative care. He lectures widely and has published over 60 papers in peer-reviewed journals in the areas of palliative care, spirituality, family caregiving, and end-of-life care education.

An expert in Community-Based Palliative Care, Dr. Rabow also serves as a consultant to medical centers nationally working to develop or expand their palliative care services, and as a consultant to numerous prominent professional or philanthropic organizations dedicated to expanding palliative care access and quality. Dr. Rabow served as the lead of the project advisory board for the "Improving Palliative Care in the Outpatient Setting" (IPAL-OP) initiative at the Center to Advance Palliative Care. He directed the outpatient palliative care service assessment team for the National Comprehensive Cancer Network. Dr. Rabow is on the advisory board to the Palliative Care Institute of the California State University at San Marcos, which provides online education and certification for members of the palliative care interdisciplinary team.

Dr. Rabow is one of the leads of the UCSF Palliative Care Leadership Center (PCLC) and a member of the curriculum development committee for the PCLC Initiative nationally.

Tiffany, a California native, worked at the University of California, San Francisco. Dr. Rabow is the founding director of the Center for Genitourinary Medical Oncology at The University of Texas, MD Anderson Cancer Center in Houston, Texas. Prior to moving to Texas, Tiffany, a California native, worked at the Keck Medical Center of USC in Los Angeles where she was an office coordinator in the Department of Clinical Social Work for almost 5 years. Prior to that, Tiffany worked various healthcare jobs in various settings. In total, Tiffany has more than 15 years working in the healthcare field and says that her desire to help people get the care needed is what has kept her in healthcare this long.

Tiffany obtained her BS degree in Business Administration and MBA degree from Mount Saint Mary’s University, Los Angeles. Tiffany was also recently admitted to the Sigma Delta Beta Delta International Honor Society for Business, Management, and Administration. Tiffany sits on the Board of Directors for the California Prostate Cancer Coalition as its Secretary and is honorary staff member for the National Alliance of State Prostate Cancer Coalitions. Tiffany is a uterine cancer survivor herself and understands the importance of early detection, education, and playing an active role in your health.

RICHARD RIDINGTON

Richard Ridington has worked in healthcare, environmental restoration, and high tech. Treated for prostate cancer in 2016, he has since become an advocate for informed decision-making, volunteering as a member of the UCSF Urology Patient Services Committee and the Marin Prostate Cancer Info Support Group. In his spare time, he enjoys landscape photography.

The PCLC Initiative has trained more than 1000 hospital-and community-based palliative care programs in the United States. Previously, Dr. Rabow helped direct the California Hospital Initiative in Palliative Services, the first program to support the development of hospital-based palliative care services in California. In addition, Dr. Rabow served as a technical advisor and member of the leadership team for the Archstone Foundation’s Hospital-Based Palliative Care Service Innovations project.

Dr. Rabow is the founding director of the Center for Education in Palliative Care at UCSF/Mount Zion, which also serves as the central hub for palliative care education across the UCSF enterprise. Dr. Rabow is an active member of the UCSF Academy of Medical Educators. He was Assistant Editor for the bimonthly section in the Journal of the American Medical Association entitled “Perspectives on Care at the Close of Life.” This series now appears as a palliative care textbook, Care at the Close of Life. For 15 years, he served as the Director of the Center for the Study of the Healer’s Art at the Institute for the Study of Health and Illness at Commonweal in California. Dr. Rabow is the Associate Editor of the world’s best-selling annually-updated general medicine textbook, Current Medical Diagnosis and Treatment. Dr. Rabow is the executive producer of “The Caregivers” documentary film and accompanying family caregiver handbook. (continued on next page)
MACK ROACH III, MD
Dr. Mack Roach III is a radiation oncologist and an internationally renowned expert on treating and managing prostate cancer.

Dr. Roach is a Professor of Radiation Oncology, Medical Oncology and Urology, at the University of California, San Francisco. He earned his MD from Stanford University School of Medicine. Dr. Roach has gained international recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning recently published by the American College of Radiology. He is a member of several professional societies including the American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, Radiation Therapy Oncology Group, the NCI IMRT Working Group and American Joint Commission for Cancer (AJCC) Staging (GU), the American Cancer Society (ACS) Task for Cancer Screening Guidelines (Prostate cancer) and the NCI Concept Evaluation Panel (Prostate Cancer Phase III Trials).

Dr. Roach’s major research interest involves the application of 3-D conformal and intensity modulated radiotherapy (IMRT) as a major component of combined modality management of prostate cancer and other solid tumors. Over the last 12 years his research efforts have been directed at defining optimal imaging modalities, criteria for target definitions, development of improved treatment techniques, as well as the prediction of complication probabilities. This work has found expression in the Clinical Trials Cooperative Group Mechanism. He chaired a large prospective randomized trial comparing different strategies for locally advanced prostate cancer.

Dr. Roach has gained recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning, recently published by the American College of Radiology. He has begun to pioneer intensity modulated radiotherapy (IMRT), in combination with Online Portal Imaging, and improved dose calculation algorithms that should allow UCSF Radiation Oncology to provide leadership in the field of radiotherapy for many years to come. Roach is considered a foremost authority in disparities in outcomes from cancer treatment in underserved populations. A recently funded NIH U-56 cooperative planning grant with San Francisco State University should allow both institutions to build a program to effectively address this area in years to come.

STAN ROSENFELD
Stan Rosenfeld was diagnosed with prostate cancer in 1997. He became an expert meta-researcher, and now, believing that knowledge is power, he has dedicated himself to educating men on how to reduce their risk of getting prostate cancer, the importance of early detection, and the importance of guidance through the decision process with a diagnosis of prostate cancer.

Stan Rosenfeld chairs UCSF’s Urology Patient Services Committee, and has been a long-time patient advocate for UCSF. He is also a Member of UCSF’s Prostate Cancer Leadership Program. He is a charter participant in UCSF’s Peer-to-Peer Program which offers one-on-one help for men with prostate cancer; and serves on the UCSF Patient and Family Advisory Council.

Mr. Rosenfeld serves on the Executive Board of Directors of the California Prostate Cancer Coalition (CPCC), a not-for-profit 501(c)(3) organization formed in 1997. CPCC is the co-presenter of this conference: The 2019 CPCC/UCSF Patient Conference on Prostate Cancer. He has led CPCC’s Best Practices Workshops for Support Group Leaders yearly in Northern and Southern California since 2000.

Stan Rosenfeld is a member of the Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN). He is also a Member of the Oncology Committee of Marin General Hospital and a Member of the Marin General Hospital Patient and Family Advisory Council.

Stan Rosenfeld has been facilitating a weekly support group for men with prostate cancer at Marin General Hospital since 2000. He is a member of the US TOO International Help Desk. Stan is especially interested in Quality of Life Issues and is working on several projects in the area of treatment decisions.

ALAN SHINDEL, MD
Dr. Alan W. Shindel is a urologist who specializes in sexual function and dysfunction, androgen biology in men and chronic pelvic pain syndromes.

Dr. Shindel’s research interests include medical student education, sexual wellness and new methods for assessing bladder and pelvic pain conditions.

Dr. Shindel earned his medical degree and completed a residency in urology at Washington University School of Medicine in St. Louis. He completed a fellowship in andrology – men’s health – at UCSF. He then earned a master of advanced study degree in clinical research at the University of California, Davis.

Dr. Shindel is an associate editor of the Journal of Sexual Medicine, and serves on the Sexual Medicine Society of North America’s executive board and on the male sexual dysfunction guidelines panel for the American Urological Association. He is also on the admissions committee for UCSF School of Medicine.

ERIC J. SMALL, MD, FASCO
Eric J. Small, MD, is a professor of medicine and urology at the University of California, San Francisco, where he is leader of the Prostate Cancer Program, and Deputy Director and Chief Scientific Officer in the Helen Diller Family Comprehensive Cancer Center. His patient care and research is focused on prostate cancer, immunotherapy and the mechanisms of resistance to standard therapies, most recently focusing on the development of treatment associated small cell/neuroendocrine prostate cancer (t-SCNC).

Dr. Small was principal investigator for the Stand Up to Cancer West Coast Prostate Cancer Dream Team, and has been involved with the development of a number of therapeutics including abiraterone, apalutamide, sipuleucel T, and ipilimumab. Dr. Small is a member of the Board of Directors of the American Society of Clinical Oncology (ASCO).

Dr. Small earned a bachelor’s degree from Stanford University and a medical degree from Case Western Reserve University School of Medicine. While in medical school, he completed a fellowship in pathology. He completed post-graduate residency training in internal medicine at Beth Israel Hospital (Boston) and a fellowship in hematology and oncology at UCSF before joining the UCSF faculty.

FACULTY BIOS (continued)
TIA WEINBERG
Tia Weinberg is the Program Coordinator of the Patient Support Corps at UCSF. Tia participated in the Patient Support Corps for three years as an undergraduate student intern from UC Berkeley. Her responsibilities include coordinating the current pre-health interns to serve as telephone coaches, patient scribes, and advocates. The Patient Support Corps helps with three proven support strategies, helping patients review information, list questions and make notes and recordings.

WALT TRASK
Walt Trask is a prostate cancer survivor who has spent the past 30 years as an international trade finance specialist in commercial banking. He is currently Senior Vice President in International trade Finance at Comerica Bank. Walt holds a BA in Economics/Latin American Studies from SUNY Oswego, and an International MBA from the University of San Diego. Walt gives back to the prostate cancer community, among other ways, by his active participation on the UCSF Urology Patient Services Committee. Walt also participates in the Marin Prostate Cancer Support Group where he maintains the Patient Database.

R. JAMES YU, MD
Dr. James Yu has superior expertise in robotic surgery for urological cancers which is an asset to the healthcare community at large. After graduating from the USC Keck School of Medicine with Highest Distinction and Alpha Omega Alpha honors, Dr. Yu went on to Stanford University where he completed his internship and residencies in General Surgery and Urology. Dr. Yu further refined his surgical expertise with fellowship training in Advanced Robotics and Laparoscopy at the USC Institute of Urology under the direction of Dr. Inderbir Gill. Dr. Yu’s focus is on urologic oncology with specific expertise in minimally invasive surgery for diseases of the adrenal, kidney, ureter, bladder and prostate.

Dr. Yu’s training at Stanford and USC has allowed him to synthesize various technical approaches as practiced at Johns Hopkins, Memorial-Sloan-Kettering, Cleveland Clinic, UCLA, USC and Stanford. He combines the best of these techniques to achieve exceptional oncologic and quality of life outcomes in all urologic cancers.

Dr. Yu’s research interests focus on the development of medical devices for unmet clinical needs in urologic and cardiovascular disease. He has received multiple grants from the NIH, Coulter Foundation, and NCIIA for medical device innovation and has multiple patents issued and pending. He also serves as reviewer for multiple urology journals.

LOCATION MAP
UCSF Cole Hall Auditorium
513 Parnassus Avenue
San Francisco, CA  94143
THE CALIFORNIA PROSTATE CANCER COALITION RECOMMENDS THAT YOU TAKE CHARGE!

• Become knowledgeable about your health and about prostate cancer
• Encourage all men to have a PSA and a DRE at the appropriate ages and intervals
• Keep a written record of your PSA levels to observe any changes
• Encourage and adopt healthy lifestyle changes to reduce risk and for better cancer outcomes
  - Add more fruits and vegetables to your diet and replace animal protein
  - Vitamin D, green tea and tomato products may reduce prostate cancer risk
  - Eat more whole grains and legumes
  - Exercise
  - Reduce stress
• Know your family medical history
• Join a Support Group!
• Spread the word about Informed Decision-Making and distribute our Informed Decision-Making Laminate when possible
• Advocate for the early diagnosis and treatment of potentially deadly prostate cancer
• Learn about clinical trials for cancer patients
• Participate in outreach programs and help spread the word about Early Detection
• Become an advocate for lessening the burden of prostate cancer

CPCC CAN HELP YOU:

• Find your local support group
• Find others who share your diagnosis
• Find a place to turn for help when you have been diagnosed
• Find links to other resources
• Keep up to date on prostate cancer news and other information
• Become informed and aware

June 2019
CPCC and UCSF wish to thank the following sponsors of the 2019 Patient Conference on Prostate Cancer for their generosity:

- Genomic Health
- Abbvie
- Dendreon
- CyberKnife
- Janssen Oncology

CPCC and UCSF would also like to thank the anonymous large donor who joined in the effort to make this conference a success!